Home > Animal Health & Nutrition > Pet Cancer Therapeutics Market

Pet Cancer Therapeutics Market - By Therapy (Chemotherapy, Immunotherapy, Targeted Therapy, Combination Therapy), By Route of Administration (Oral, Injection), By Species (Dogs, Cats), & Application, Global Forecast, 2023-2032

  • Report ID: GMI2017
  • Published Date: Mar 2023
  • Report Format: PDF

Pet Cancer Therapeutics Market Size

Pet Cancer Therapeutics Market size registered a valuation of over USD 369 billion in 2022 and is slated to exhibit more than 10% CAGR from 2023 to 2032 driven by the increasing willingness of pet parents to spend on their pets’ healthcare.

Pet Cancer Therapeutics Market

To understand key trends  
Download Free Sample

The industry need is primarily fueled by a swelling number of pet cancer cases. The upsurge in canine & feline cancer is primed to drive the demand for effective pet cancer therapeutics to manage cancer conditions, further driving the business progress. According to the Merck Veterinary Manual, genetic factors can contribute to the development of cancer in companion animals. Additionally, positive efforts to improve canine therapies such as government funding have uplifted the industry outlook.

Furthermore, significant awareness among pet owners concerning pet diseases is expected to stimulate industry expansion. The growing understanding of pet cancer and commercially available treatments is boosting the demand for therapeutics and has broadened the use of these products. The prevalence of smartphones and the information available online have greatly increased pet owners' understanding of various illnesses.

Side effects associated with pet cancer therapies may restrain industry progression

Adverse effects from pet cancer therapies are a major factor restraining pet cancer therapeutics market share. Similar to humans, chemotherapy in dogs and cats causes low white blood cell count, vomiting, dehydration, diarrhea, lethargy, and bladder irritation. In September 2022, the FDA warned pet owners regarding a potential threat to dogs with skin cancer cream fluorouracil or 5-FU due to consistent deaths of dogs. Nonetheless, recent breakthroughs in cancer treatment for pets are expected to be beneficial for the market landscape.

Pet Cancer Therapeutics Market Analysis

Global Pet Cancer Therapeutics Market Share By Therapy

To understand key market trends  
Download Free Sample

Pet cancer therapeutics market from the chemotherapy segment is set to be worth more than USD 628 million by 2032. The most common treatment of lymphoma cancer treatment, particularly for companion animals, is chemotherapy. According to a study by the Flint Animal Cancer Center, canine lymphoma accounting for almost 24% of all new cases of canine cancer in 2019, was one of the most frequently diagnosed diseases in dogs.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Global market size for pet cancer therapeutics was valued at more than USD 369 billion in 2022 and is set to progress at over 10% CAGR from 2023 to 2032 owing to the increasing willingness of pet parents to spend on their pets’ healthcare.

Mast cell cancer application segment is anticipated to witness growth at 8.5% CAGR through 2032 due to increased incidence of respective malignancy affecting the gastrointestinal system, bone marrow, liver, and spleen, especially in dogs.

Oral route of administration segment is projected to reach more than USD 359 million by the end of 2032 as a result of soaring developments in oral medicines due to their clinical benefits, including the ease & comfort of home therapy and fewer clinic visits.

North America pet cancer therapeutics market is slated to be worth more than USD 774 million by 2032 on account of high veterinary health spending, an increase in the occurrences of pet cancer, and government measures to encourage pet cancer research in the region.

Pet Cancer Therapeutics Market Scope

Buy Now

Access to only 1 person; cannot be shared; cannot be printed
Access for 2 to 5 users only within same department of one company
Access to a company wide audience; includes subsidiary companies or other companies within a group of companies
Immediate Delivery Available

Premium Report Details

  • Base Year: 2022
  • Companies covered: 8
  • Tables & Figures: 241
  • Countries covered: 21
  • Pages: 140
 Download Free Sample